Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01835925 · ClinicalTrials.gov registry record

Rectal Cancer Consortium

A clinical trial of Rectal Cancer, sponsored by Brown University.

Completed
Registry status
12
Enrollment target
2
Study locations

NCT01835925 is a study of Rectal Cancer that has completed, run by Brown University. The registered enrollment target is 12 participants, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01835925, a study of Rectal Cancer, has completed, sponsored by Brown University.

COMPLETED
Registry status
12 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to study which genes are abnormal in rectal cancer and see if this predicts how well chemotherapy and radiation will reduce the size of cancer and whether cancer recurs after surgery.

Conditions Studied

Interventions

  • GENETIC Tissue specimen

Study Locations (2)

Rhode Island

  • Rhode Island Hospital - Providence
  • The Miriam Hospital - Providence

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2013-07
Est. Completion 2014-04

Sponsor

Brown University

231 total trials

What the Registry Record Tells You About NCT01835925

The ClinicalTrials.gov registry entry for NCT01835925 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tissue specimen is the first listed.

NCT01835925 reports 2 study locations spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT01835925 about?

NCT01835925 is a clinical study titled "Rectal Cancer Consortium". The purpose of this study is to study which genes are abnormal in rectal cancer and see if this predicts how well chemotherapy and radiation will reduce the size of cancer and whether cancer recurs after surgery.

What is the current status of trial NCT01835925?

This trial is currently completed. The enrollment target is 12 participants. The study started on 2013-07. Estimated completion is 2014-04.

What conditions does trial NCT01835925 study?

This clinical trial studies the following conditions: Rectal Cancer.

What interventions are being tested in trial NCT01835925?

The interventions under investigation include: Tissue specimen (GENETIC).

Who is sponsoring clinical trial NCT01835925?

This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01835925 being conducted?

This trial has 2 study locations across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.